---
title: Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20
  Bispecific Antibody Therapy
date: '2024-01-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38252906/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240123170622&v=2.18.0
source: Blood
description: Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new
  milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs
  have demonstrated remarkable single-agent activity in heavily pretreated patients,
  and at least three have so far received regulatory approvals in various countries.
  However, BsAbs can lead to potentially severe toxicity associated with T-cell activation,
  particularly cytokine release syndrome (CRS). The anticipated widespread use of
  ...
disable_comments: true
---
Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have demonstrated remarkable single-agent activity in heavily pretreated patients, and at least three have so far received regulatory approvals in various countries. However, BsAbs can lead to potentially severe toxicity associated with T-cell activation, particularly cytokine release syndrome (CRS). The anticipated widespread use of ...